A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 17 Mar 2017 Planned End Date changed from 1 Jan 2019 to 18 Jan 2019.
    • 27 May 2016 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top